Press Room

2023 CPhI Worldwide

Tuesday, October 24, 2023 - 00:00
Thursday, October 26, 2023 - 00:00
Location: Barcelona, Spain
Booth Number: 3L20
2023_CPhI Barcelona_Hovione

Join Hovione at CPhI Worldwide and meet the team in whose attentive hands you can place your project.

Let’s discuss your project together.

Schedule a meeting button | Hovione



We look forward to seeing you at CPhI Worldwide

to present the most reliable and innovative end-to-end solutions to help your project succeed.


Also interested:

The Future is Continuous

Meet our experts and find out if
Continuous Tableting is right for your product​​​​​


The Leader in Spray Drying

Contact our experts to overcome your
solubility issues with the best scale-up science



Learn more about the innovative technology
capable of solving the poor solubility issues of your drug candidate


Meet our experts to identify the best performing
and stable formulations for your drug

Everything for Inhalation

Meet our experts to bring your
Inhaled medicine to patients

The Specialist Integrated CDMO

Contact our experts to take your project
to market faster​​​


Schedule a meeting with our experts.


Find more about CPhI Worldwide.


Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at  


Continuous Tableting and the Road to Global Adoption

Mar 04, 2024